March 10, 2022
Novartis Signs Initial Agreement with Carisma Therapeutics for the Manufacturing of HER 2 Targeted CAR-M Cell Therapy
Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.